The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 22: 2974 - 2978

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.22.020

Drugs and Clinic Practice

Comparison of therapeutic effects between single⁃dose CTX intravenous pulse therapy and IVIG pulse therapy for severe gastrointestinal involvement of Henoch Schönlein purpura in children

  • Yalan HU ,
  • Ting WANG ,
  • Qiang. FU
Expand
  • Department of Pediatrics，Jingzhou Hospital Affiliated to Yangtze University，Jingzhou 434020，China

Received date: 2023-06-06

  Online published: 2023-12-11

Fold

Abstract

Objective The study aimed to explore the efficacy and safety of single?dose CTX intravenous pulse therapy for severe gastrointestinal involvement of Henoch Sch?nlein purpura in children. Methods A total of 256 children with abdominal Henoch?Sch?nlein purpura admitted to the Department of Pediatrics of Jingzhou Hospital affiliated to Yangtze University from January 1 in 2017 to June 1 in 2022 were divided into three groups according to the pain digital evaluation scale （NRS?11） and clinical characteristics，which were common type group （157 cases） and severe type group （99 cases）. According to the different treatment options of IVIG and CTX， the severe group was divided into IVIG group （53 cases） and CTX group （46 cases）. 50 healthy children admitted to the hospital for physical examination during the same period were selected as the control group. The changes of laboratory indicators were compared in each group， and the drug efficacy， repeated conditions， complications and adverse reactions were analyzed. Results There was no difference in all laboratory indicators between the healthy control group and the common type group （P > 0.05）. Compared with common type group， WBC， NE and CRP were significantly higher in severe group （P < 0.05）； HGB， ALB and IgG were significantly decreased （P < 0.05）； there was no difference in RDW， PLT， Cr， CystatinC， IgA， C3 and C4 （P > 0.05）. Meanwhile， there was no difference in laboratory indicators between the CTX group and the IVIG group before treatment. Resolution of abdominal pain， hemafecia， time of fasting， duration of intravenous methylprednisolone and the average hospitalization were significantly shortened （P < 0.05）； cumulative use of methylprednisolone， recurrence of abdominal pain and new rashes were significantly reduced （P < 0.05）. In addition， there were no obvious adverse reactions in CTX group， such as hemorrhagic cystitis， leukopenia or severe gastrointestinal reactions. Conclusion When the child is in a high inflammatory state and low IgG level， and it is difficult to withdraw the high dose of glucocorticoid， the early use of single?dose CTX intravenous treatment could quickly control the disease activity， reduce the amount of glucocorticoid， decrease the recurrence rate of bloody stools and abdominal pain， and have no obvious adverse reactions. The efficacy is superior to IVIG.

Key words： abdominal henoch?sch?nlein purpura; severe; cyclophosphamide sepsis; glucocorticoid; IVIG; children

Cite this article

Yalan HU , Ting WANG , Qiang. FU . Comparison of therapeutic effects between single⁃dose CTX intravenous pulse therapy and IVIG pulse therapy for severe gastrointestinal involvement of Henoch Schönlein purpura in children[J]. The Journal of Practical Medicine, 2023 , 39(22) : 2974 -2978 . DOI: 10.3969/j.issn.1006-5725.2023.22.020

References

1 NAIFA G， TOTIKIDIS G， ALEXIADOU S， et al. Intravenous γ Globulin for Intractable Abdominal Pain due to IgA Vasculitis［J］. Case Rep Pediatr，2020，2020：8867621.
2 ZHU Y， DONG Y， WU L， et al. Changes of inflammatory mediators andoxidative stress indicators in children with Henoch-Sch?nlein purpuraand clinical effects of hemoperfusion in the treatment of severe Henoch-Sch?nlein purpura with gastrointestinal involvement in children［J］. BMC Pediatr，2019，19（1）： 409-412.
3 中华医学会儿科学分会肾脏学组. 紫癜性肾炎诊治循证指南（2016） ［J］. 中华儿科杂志，2017，55（ 9 ）： 647-651.
4 江载芳，申昆玲，沈颖. 《诸福棠实用儿科学》［M］. 8版. 北京： 人民卫生出版社，2015：773-775.
5 CASTARLENAS E， SáNCHEZ-RODRíGUEZ E， VEGA RDE L， et al. Agreement between verbal and electronic versions of the numerical rating scale （NRS-11） when used to assess pain intensity in adolescents ［J］. Clin J Pain， 2015，31（3）：229-234.
6 DELALEU J， LEPELLETIER C， CALUGAREANU A，et al. Neutrophilic dermatoses［J］. Rev Med Interne， 2022， 43（12）：727-738.
7 朱小波，范海燕，刘金祥. 山莨菪碱结合孟鲁司特治疗过敏性紫癜患儿的临床研究及复发的危险因素分析［J］.实用医学杂志，2021，37（3）：385-389.
8 XU L， LI Y， WU X.IgA vasculitis update： Epidemiology， pathogenesis，and biomarkers［J］. Front Immunol，2022，13：921864.
9 ZELLER J， BOGNER B， KIEFER J， et al.CRP Enhances the Innate Killing Mechanisms Phagocytosis and ROS Formation in a Conformation and Complement-Dependent Manner［J］. Front Immunol， 2021， 12：721887.
10 ZINELLU E， FOIS A G， SOTGIU E， et al. Serum Albumin Concentrations in Stable Chronic Obstructive Pulmonary Disease： A Systematic Review and Meta-Analysis.［J］.J Clin Med， 2021， 10（2）：269.
11 FRATICELLI P， BENFAREMO D， GABRIELLI A. Diagnosis and management of leukocytoclastic vasculitis［J］.Intern Emerg Med， 2021，16（4）： 831-841.
12 GUO Q， HU X， SONG C， et al.Clinical characteristics and associating risk factors of gastrointestinal perforation in children with IgA vasculitis［J］.Ann Med，2021， 53（1）：2315-2320.
13 YANG X， LI Q， HE Y， et al. Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis［J］.Front Pharmacol， 2022，13：956397.
14 傅桐，赵成广，侯玲，等. 229例儿童IgA血管炎腹部受累诊治分析［J］.中国小儿急救医学，2021，28（9）：791-796.
15 DYGA K， SZCZEPA?SKA M. IgA vasculitis with nephritis in children［J］.Adv Clin Exp Med， 2020， 29（4）：513-519.
16 BA?ARAN ?， CAKAR N， UNCU N，et al. Plasma exchange therapy for severe gastrointestinal involvement of Henoch Sch?nlein purpura in children［J］. Clin Exp Rheumatol，2015， 33（ 89）：176-180.
17 何逾祥，朱伟雪. 环磷酰胺在重症腹型过敏性紫癜治疗中的临床效果观察［J］.中国现代药物应用，2019，13（23）：112-114.
18 ELMARIAH H， FUCHS E J. Post-transplantation cyclophosphaAmide to facilitate HLA-haploidentical hematopoietic cell transplantation：Mechanisms and results［J］. Semin Hematol，2022，56（3）：183-189.
19 MALPICA L， MOLL S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids，antimetabolites， cyclosporinemand cyclophosphamide in nonmalignant hematologic diseases［J］. Hematology Am Soc Hematol Educ Program， 2020，2020（1）：319-327.
20 LEVINE T D， KATZ J S， BAROHN R， et al. Review process for IVIG treatment： Lessons learned from INSIGHTS neuropathy study［J］. Neurol Clin Pract， 2018，8（5）： 429-436.
21 MANGER K， WILDT L， KALDEN J R， et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide： the PREGO-Study［J］. Autoimmun Rev，2006，5（4）：269-272.
Options
Outlines

/

〈 〉